Profile data is unavailable for this security.
About the company
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
- Revenue in USD (TTM)27.77m
- Net income in USD2.32m
- Incorporated1987
- Employees70.00
- LocationImmuCell Corp56 Evergreen DrivePORTLAND 04103United StatesUSA
- Phone+1 (207) 878-2770
- Fax+1 (302) 655-5049
- Websitehttps://immucell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhengye Biotechnology Holding Ltd | 22.25m | -2.80m | 45.54m | 277.00 | -- | 1.05 | 134.80 | 2.05 | -0.059 | -0.059 | 0.4787 | 0.9131 | 0.3099 | 1.62 | 2.04 | 80,341.63 | -4.60 | -- | -7.79 | -- | 37.37 | -- | -14.83 | -- | 1.10 | -7.00 | 0.1902 | -- | -11.95 | -- | -64.04 | -- | -- | -- |
| RADNOSTIX, INC. | 14.07m | -231.26k | 48.72m | 41.00 | -- | 11.89 | 289.47 | 3.46 | -0.0004 | -0.0004 | 0.0268 | 0.0078 | 0.8147 | 5.96 | 8.18 | 343,260.30 | -1.34 | 1.32 | -1.68 | 1.95 | 59.89 | 59.45 | -1.64 | 1.95 | 1.06 | -0.2928 | 0.5954 | 0.00 | 13.31 | 9.19 | 100.99 | -- | 28.22 | -- |
| Odonate Inc | 0.00 | -102.07m | 52.65m | 137.00 | -- | 2,022.38 | -- | -- | -108.70 | -108.70 | 0.00 | 74.17 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Nasus Pharma Ltd | 0.00 | -1.19m | 53.18m | -- | -- | -- | -- | -- | -0.1319 | -0.1383 | 0.00 | -0.4762 | 0.00 | -- | -- | -- | -373.32 | -- | -- | -- | -- | -- | -- | -- | -- | -2.51 | -- | -- | -- | -- | -54.23 | -- | -- | -- |
| Janel Corp | 207.44m | 5.03m | 56.94m | 353.00 | 11.50 | 2.21 | 6.62 | 0.2745 | 4.18 | 4.18 | 172.09 | 21.75 | 1.47 | 32.80 | 4.14 | 587,657.30 | 4.02 | 1.76 | 13.35 | 5.33 | 31.33 | 26.69 | 2.73 | 0.9608 | 0.7013 | 3.10 | 0.3913 | 0.00 | 13.24 | 20.27 | 2,155.61 | -- | -14.58 | -- |
| Cumberland Pharmaceuticals, Inc. | 41.28m | -3.33m | 58.03m | 91.00 | -- | 2.22 | 45.99 | 1.41 | -0.2331 | -0.2331 | 2.79 | 1.75 | 0.5788 | 1.72 | 3.80 | 453,608.30 | -4.68 | -6.88 | -7.60 | -9.65 | 84.49 | 80.74 | -8.09 | -15.89 | 1.11 | -28.41 | 0.1688 | -- | -4.26 | 1.95 | -3.19 | -- | -29.32 | -- |
| ImmuCell Corp | 27.77m | 2.32m | 59.70m | 70.00 | 25.51 | 2.00 | 11.89 | 2.15 | 0.2588 | 0.2588 | 3.09 | 3.29 | 0.6159 | 1.90 | 11.42 | 402,453.60 | 5.15 | -5.35 | 5.69 | -5.77 | 40.93 | 36.02 | 8.37 | -11.87 | 1.76 | 6.47 | 0.2415 | -- | 51.64 | 14.06 | 62.65 | -- | -19.66 | -- |
| Rafael Holdings Inc | 1.03m | -31.33m | 62.12m | 21.00 | -- | 0.738 | -- | 60.36 | -0.8471 | -0.8471 | 0.0284 | 1.63 | 0.0107 | -- | 3.35 | 49,000.00 | -32.33 | -45.03 | -37.62 | -51.75 | 89.70 | -- | -3,034.89 | -8,772.74 | 3.98 | -- | 0.0074 | -- | 43.96 | -28.51 | 11.30 | -- | -47.65 | -- |
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 63.52m | 4.00 | -- | 1.09 | -- | 8.58 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| LifeVantage Corp | 210.05m | 7.86m | 64.35m | 232.00 | 8.39 | 1.95 | 5.97 | 0.3064 | 0.5998 | 0.5998 | 16.16 | 2.58 | 3.24 | 2.45 | 96.73 | 905,370.70 | 12.12 | 9.17 | 18.91 | 14.08 | 78.75 | 80.73 | 3.74 | 2.93 | 1.03 | -- | 0.00 | 35.06 | 14.17 | -0.3794 | 233.84 | -3.22 | -12.55 | -- |
| MindWalk Holdings Corp | 14.99m | -22.76m | 64.90m | 102.00 | -- | 4.93 | -- | 4.33 | -0.6323 | -0.6139 | 0.3516 | 0.2817 | 0.4745 | 6.67 | 4.50 | -- | -72.01 | -32.32 | -90.53 | -36.45 | 58.50 | 55.79 | -151.78 | -100.97 | 4.09 | -23.68 | 0.17 | -- | 0.0082 | 11.77 | -11.25 | -- | 10.37 | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 68.21m | 171.00 | -- | 0.3405 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| NovaBay Pharmaceuticals Inc | 2.83m | -7.95m | 68.45m | 14.00 | -- | -- | -- | 24.19 | -1.58 | 0.5377 | 0.555 | 0.2718 | 0.7686 | -- | 5.28 | 202,142.90 | -215.92 | -61.58 | -404.37 | -83.79 | 54.56 | 59.49 | -280.92 | -77.39 | -- | -91.56 | 0.0836 | -- | -33.58 | 8.19 | 48.52 | -- | -20.59 | -- |
| Scilex Holding Co | 40.36m | -375.84m | 70.56m | 30.00 | -- | -- | -- | 1.75 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
Data as of Feb 13 2026. Currency figures normalised to ImmuCell Corp's reporting currency: US Dollar USD
11.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 260.33k | 2.88% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 150.69k | 1.67% |
| Cresset Asset Management LLCas of 30 Sep 2025 | 132.00k | 1.46% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 124.72k | 1.38% |
| Bleichroeder LPas of 31 Dec 2025 | 101.59k | 1.12% |
| Dauntless Investment Group LLCas of 30 Sep 2025 | 87.12k | 0.96% |
| Geode Capital Management LLCas of 31 Dec 2025 | 72.26k | 0.80% |
| Steadtrust LLCas of 31 Dec 2025 | 56.77k | 0.63% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 46.01k | 0.51% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 42.67k | 0.47% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
